
About Indica Pharmaceuticals Private Limited
Data last updated:
Indica Pharmaceuticals Private Limited is a private limited company based in Ahmedabad, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 17 September 2020 and has been in existence for over 6 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN U24110GJ2020PTC116614. Its GSTIN is 24AAFCI8107A1Z3 (Gujarat).
The company has an authorised share capital of ₹1.5 Lakh and a paid-up capital of ₹1.5 Lakh. It is led by directors Siddharth Patel and Narendrakumar Ramanlal Patel.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 1082/A/B B/H Anil Satrch Arvind Ind Estate Nr Nicol Tol Naka, Ahmedabad, Gujarat, India – 382345.
As per the financials filed for FY 2024, the company reported a revenue of ₹4 Cr, a decline of 17% compared to the previous year. For the same year it recorded a net profit of ₹7.51 Lakh (net margin 1.9%) and EBITDA of ₹19.96 Lakh (EBITDA margin 5%). Revenue has grown at a compounded annual rate (CAGR) of 38% over three years.
The company has about 9 employees on its provident fund (EPFO) records.
For more details, the company can be reached via its website indicalaboratoriespvtltd.com.
Company details
Contact details
Indica Pharmaceuticals Private Limited's registered office is in Ahmedabad, Gujarat. Its website is indicalaboratoriespvtltd.com. Its e-mail address is in the company report.
- Email
- Website
- Registered Address1082/A/B B/H Anil Satrch Arvind Ind Estate Nr Nicol Tol Naka, Ahmedabad, Gujarat, India – 382345
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Indica Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Indica Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Indica Pharmaceuticals Private Limited, buy the company report.
Financials of Indica Pharmaceuticals Private Limited
FY 2025 filings availableIndica Pharmaceuticals Private Limited reported revenue of ₹4 Cr (down 17% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR)
Revenue fell 17% in the latest year, but over three years it has grown at a compounded annual rate (CAGR) of 38%. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|
| Profit and Loss Statement | ||||
| Revenue from Operations | ||||
| Other Income | ||||
| Total Revenue | ||||
| Cost of Materials Consumed | ||||
| Employee Benefit Expense | ||||
| Finance Costs | ||||
| Depreciation and Amortisation | ||||
| Other Expenses | ||||
| Total Expenses | ||||
| EBITDA | ₹19.96 Lakh | |||
| Profit Before Tax | ||||
| Tax Expense | ||||
| Net Profit (PAT) | ₹7.51 Lakh | |||
| Balance Sheet | ||||
| Share Capital | ||||
| Reserves and Surplus | ||||
| Net Worth (Total Equity) | ||||
| Long-term Borrowings | ||||
| Short-term Borrowings | ||||
| Trade Payables | ||||
| Total Liabilities | ||||
| Fixed Assets | ||||
| Investments | ||||
| Inventories | ||||
| Trade Receivables | ||||
| Cash and Bank Balance | ||||
| Total Assets | ||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|
| Profitability | ||||
| EBITDA Margin | 5% | |||
| Net Profit Margin | 1.9% | |||
| Return on Equity (ROE) | ||||
| Return on Capital Employed (ROCE) | ||||
| Return on Assets (ROA) | ||||
| Liquidity and Debt | ||||
| Current Ratio | ||||
| Quick Ratio | ||||
| Debt-to-Equity Ratio | ||||
| Interest Coverage Ratio | ||||
| Efficiency and Growth | ||||
| Asset Turnover | ||||
| Receivable Days | ||||
| Payable Days | ||||
| Inventory Days | ||||
| Revenue Growth | ||||
| Net Profit Growth | ||||
To see the full financial statements and ratios of Indica Pharmaceuticals Private Limited, buy the company report.
Board of directors of Indica Pharmaceuticals Private Limited
Indica Pharmaceuticals has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Siddharth Patel | Director | 17 Sep 2020 | 6 Years 2 Months | Current |
| Narendrakumar Ramanlal Patel | Director | 17 Sep 2020 | 6 Years 2 Months | Current |
Legal cases
No court or tribunal cases involving Indica Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Indica Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Indica Pharmaceuticals Private Limited has a workforce of 9 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 9 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 |
To see the full employee and EPFO history of Indica Pharmaceuticals Private Limited, buy the company report.
GST
Indica Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AAFCI8107A1Z3 | Gujarat | Active | 25 Sep 2020 |
To see the full GST registrations and return filing status of Indica Pharmaceuticals Private Limited, buy the company report.
Recent activity
Indica Pharmaceuticals Private Limited has 2 board changes on record since 2020: 2 appointments. The latest: Narendrakumar Ramanlal Patel was appointed as Director on 17 Sep 2020.
Frequently asked questions
Indica Pharmaceuticals is an active private limited company based in Ahmedabad, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 17 September 2020 (6+ years old) and is registered under CIN U24110GJ2020PTC116614.
Indica Pharmaceuticals has 2 current directors:
- Siddharth Patel - Director
- Narendrakumar Ramanlal Patel - Director
The latest financial statements of Indica Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2021 are in the company report.
The GSTIN of Indica Pharmaceuticals is 24AAFCI8107A1Z3, registered in Gujarat.
The CIN (Corporate Identification Number) of Indica Pharmaceuticals is U24110GJ2020PTC116614. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Indica Pharmaceuticals was incorporated on 17 September 2020, making it 6+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Narendrakumar Ramanlal Patel was appointed as Director on 17 Sep 2020. Siddharth Patel was appointed as Director on 17 Sep 2020.
Indica Pharmaceuticals can be reached through the website indicalaboratoriespvtltd.com. Its registered office is in Ahmedabad, Gujarat, India.
The registered office of Indica Pharmaceuticals is at 1082AB BH Anil Satrch Arvind Ind Estate Nr Nicol Tol Naka, Ahmedabad, Gujarat, India – 382345.
Indica Pharmaceuticals operates in the pharma industry, in the drug formulation and development segment.

